| Literature DB >> 34029626 |
F Chiappa1, B Frascella1, G P Vigezzi1, M Moro2, L Diamanti3, L Gentile4, P Lago4, N Clementi5, C Signorelli6, N Mancini5, A Odone7.
Abstract
The ongoing pandemic of COVID-19 has underlined the importance of adopting effective infection prevention and control (IPC) measures in hospital and community settings. Ultraviolet (UV)-based technologies represent promising IPC tools: their effective application for sanitation has been extensively evaluated in the past but scant, heterogeneous and inconclusive evidence is available on their effect on SARS-CoV-2 transmission. With the aim of pooling the available evidence on the efficacy of UV technologies against coronaviruses, we conducted a systematic review following PRISMA guidelines, searching Medline, Embase and the Cochrane Library, and the main clinical trials' registries (WHO ICTRP, ClinicalTrials.gov, Cochrane and EU Clinical Trial Register). Quantitative data on studies' interventions were summarized in tables, pooled by different coronavirus species and strain, UV source, characteristics of UV light exposure and outcomes. Eighteen papers met our inclusion criteria, published between 1972 and 2020. Six focused on SARS-CoV-2, four on SARS-CoV-1, one on MERS-CoV, three on seasonal coronaviruses, and four on animal coronaviruses. All were experimental studies. Overall, despite wide heterogenicity within included studies, complete inactivation of coronaviruses on surfaces or aerosolized, including SARS-CoV-2, was reported to take a maximum exposure time of 15 min and to need a maximum distance from the UV emitter of up to 1 m. Advances in UV-based technologies in the field of sanitation and their proved high virucidal potential against SARS-CoV-2 support their use for IPC in hospital and community settings and their contribution towards ending the COVID-19 pandemic. National and international guidelines are to be updated and parameters and conditions of use need to be identified to ensure both efficacy and safety of UV technology application for effective infection prevention and control in both healthcare and non-healthcare settings.Entities:
Keywords: COVID-19; Coronavirus; Disinfection; Infection control; Systematic review; Ultraviolet rays light-emitting technology
Mesh:
Year: 2021 PMID: 34029626 PMCID: PMC8139389 DOI: 10.1016/j.jhin.2021.05.005
Source DB: PubMed Journal: J Hosp Infect ISSN: 0195-6701 Impact factor: 3.926
Figure 1PRISMA flow diagram of published studies.
Characteristics of included studies
| First author | Year | Country | Study design | Target coronavirus | Medium | Study setting | Comparison |
|---|---|---|---|---|---|---|---|
| Ansaldi | 2004 | Italy | Experimental | SARS-CoV-1 | Liquid suspension | Laboratory | UV, sodium hypochlorite, ethanol, benzalkonium-chloride, chlorhexidine digluconate, 2-benzil-chlorophenol, peracetic acid, on SARS-CoV-1, influenza A and RSV |
| Bedell | 2016 | USA | Experimental | MHV-A59 and MERS-CoV | Dried MHV-A59 MERS-COV in droplets | Laboratory | UV exposed vs not exposed MHV-A59; vs UV exposed MERS-CoV |
| Bucknall | 1972 | USA | Experimental | HCoV-229E and HCoV-OC43 | Liquid suspension | Laboratory | UV irradiation and thermal inactivation of OC43 coronavirus, 229E coronavirus and influenza virus |
| Buonanno | 2020 | USA | Experimental | HCoV-229E and HCoV-OC43 | Aerosolized | Laboratory | No comparison |
| Darnell | 2004 | USA | Experimental | SARS-CoV-1 (Urbani strain) | Liquid suspension | Laboratory | UVA and UVC irradiation vs gamma irradiation, heat treatment, formaldehyde, glutaraldehyde, pH treatment |
| Duan | 2003 | China | Experimental | SARS-CoV-1 (CoV-P9 strain) | Liquid suspension | Laboratory | Resistance to UV irradiation and heating, persistence in the environment on different materials |
| Gerchman | 2020 | Israel | Experimental | HCoV-OC43 | Liquid suspension | Laboratory | No comparison |
| Heilingloh | 2020 | Germany | Experimental | SARS-CoV-2 | Liquid suspension | Laboratory | No comparison |
| Inagaki | 2020 | Japan | Experimental | SARS-CoV-2 | Liquid suspension | Laboratory | No comparison |
| Kariwa | 2006 | Japan | Experimental | SARS-CoV-1 (Hanoi strain) | Liquid suspension | Laboratory | UV irradiation vs povidone-iodine products, chemical reagents (acetone, methanol, paraformaldehyde, glutaraldehyde), heat inactivation |
| Kitagawa | 2020 | Japan | Experimental | SARS-CoV-2 | Liquid suspension | Laboratory | No comparison |
| Morilla | 1977 | USA | Experimental | TGE virus (Illinois strain and M-HP strain or cell-culture adapted strain) | Liquid suspension | Laboratory | UV irradiated Illinois field virus and M-HP tissue culture virus |
| Pratelli | 2008 | Italy | Experimental | CCV (strain S378) | Liquid suspension | Laboratory | UV irradiation vs heat, pH, formaldehyde and glutaraldehyde of CCV, vs not irradiated CCV |
| Ratnesar-Shumate | 2020 | USA | Experimental | SARS-CoV-2 (USA-WA1/2020) | Liquid suspension | Laboratory | No comparison |
| Sabino | 2020 | Brazil | Experimental | SARS-CoV-2 | Liquid suspension | Laboratory | No comparison |
| Saknimit | 1988 | Japan | Experimental | MHV (MHV-2 and MHV-N) and CCV | Liquid suspension | Laboratory | UV irradiation vs ethanol, isopropanol, benzalkonium chloride, iodophor, sodium hypochlorite, sodium chlorite, cresol soap and formaldehyde and by heating at 60°C for 15 min, on MHV, CCV, KRV, CPV |
| Simmons | 2020 | USA | Experimental | SARS-CoV-2 | Dried | Laboratory | No comparison |
| Walker | 2007 | USA and Korea | Experimental | MHV | Aerosol | Laboratory | UV irradiation of MHV, Bacteriophages MS2 and Adenovirus serotype 2 |
CCV, canine coronavirus; CPV, canine parvovirus; HCoV, human coronavirus; KRV, Kilham rat virus; MERS-CoV, Middle East respiratory syndrome-related coronavirus; MHV, murine hepatitis virus; RSV, respiratory syncytial virus; SARS-CoV-1, severe acute respiratory syndrome coronavirus 1; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TGE, transmissible gastroenteritis of swine coronavirus; UV, ultraviolet.
Ultraviolet technologies applied in included studies
| Reference | UV technology | Manufacturer | UV spectrum, wavelength (nm) | Power (W) | Intensity (Irradiance) (μW/cm2) | Other UV technology characteristics |
|---|---|---|---|---|---|---|
| Ansaldi | Not reported | Not reported | Not reported | Not reported | 40,000 (measured at the distance between the virus samples and the UV source) | Not reported |
| Bedell | Automated triple emitter whole-room UVC disinfection system | Surfacide, Naperville, IL, USA | UVC | Not reported | Not reported | n. UV emitters = 3 |
| Bucknall | Germicidal UV lamp tube | Not reported | Not reported | 60 | Not reported | n. UV emitter = 1 |
| Buonanno | Far UVC source | USHIO America, Cypress, CA, USA | UVC, 222 | 12 | 90–100 | 222-nm KrCl excimer lamp module |
| Darnell | UVA and UVC sources | Spectronics Corporation, Westbury, NY, USA | UVC, 254 | Not reported | UVC 4,016 | Not reported |
| Duan | UVC source | Not reported | UVC, 260 | Not reported | >90 (measured at the distance between the virus samples and the UV source) | Not reported |
| Gerchman | UV LED system emitting four UV spectra | AquiSense Technologies, Charlotte, NC, USA | UV, 267, 279, 286, 297 | Not reported | 267 nm: 12; 279 and 286 nm: 25; 297 nm: 32 | A circular UV LEDs system emitting at 267 and 297 nm and a custom-made rectangular UV LEDs system emitting 279 and 286 nm |
| Heilingloh | UVA and UVC sources (UV-4 S/L) | Herolab, Wiesloch, Germany | UVA, UVC | Not reported | UVC 1,940 | Not reported |
| Inagaki | Deep UV LED device | Nikkiso Co., Tokyo, Japan | UVC, 280 | Not reported | 3,750 (at 20 cm) | narrow-range wavelength (280 nm ±5) |
| Kariwa | Not reported | Not reported | Not reported | Not reported | 134 (measured at the distance between the virus samples and the UV source) | Not reported |
| Kitagawa | Krypton-chloride excimer lamp module (Care222) | Ushio Inc., Tokyo, Japan | 222-nm UV light | Not reported | 0.1 mW/cm2 | Not reported |
| Morilla | UV lamp | Not reported | Not reported | 8 | Not reported | Not reported |
| Pratelli | UVC lamp | Bio air instrument | UVC | Not reported | 27.1 (measured at 1 m, which is not the distance between the virus samples and the UV source) | Not reported |
| Ratnesar-Shumate | Solar simulator with a xenon arc lamp and optical filters | Sciencetech | UVB and UVA (range 280–400 nm) | Not reported | 1.6 W/m2 UVB, 0.7 W/m2 UVB and 0.3 W/m2 UVB | Not reported |
| Sabino | Mercury UVC lamp | UVsurface, Biolambda, Brazil | UVC, 254 | Not reported | 2.2 ± 0.2 mW/cm2 | Not reported |
| Saknimit | UV lamp (GL-15) | Toshiba | Not reported | 15 | Not reported | Not reported |
| Simmons | Pulsed-xenon UV robot | Xenen Disinfection Services, San Antonio, TX, USA | UVC | Not reported | Not reported | PX-UV robot model PXUV4D |
| Walker | UVC lamps (experimental chambers) | Lumalier, Memphis, TN, USA | UVC, 254 | 36 | Not reported | n UV emitter = 6 |
LASER, light amplification by stimulated emission of radiation; LED, light-emitting diode; UV, ultraviolet.
Results of ultraviolet (UV) light interventions on SARS-CoV-2 in included studies
| Reference | Virus | UV source | Intensity (irradiance) | Distance | Exposure time | Outcome | Results |
|---|---|---|---|---|---|---|---|
| Heilingloh | SARS-CoV-2 in liquid suspension | UV-4 S/L light source (UVC 254 nm and UVA 365 nm) | 1,940 μW/cm2 (UVC) and 540 μW/cm2 (UVA) | 3 cm | 1.4 min | Infectivity | 50% inactivation |
| 9 min | Viral titre reduction, by TCID50 | Complete inactivation | |||||
| Radiant exposure: UVA dose 292 mJ/cm2 | 3 cm | 9 min | Viral titre reduction, by TCID50 | Partial inactivation | |||
| Inagaki | SARS-CoV-2 (SARS-CoV-2/Hu/DP/Kng/19–027) in liquid suspension | Deep ultraviolet light-emitting diode (DUV-LED) | 3.75 mW/cm2 | 2 cm | 1 s | Infectivity, by CPE | 4.7*103 pfu/mL, 87.4% reduction |
| 10 s | Infectivity, by CPE | 2.7*101 pfu/mL, 99.9% reduction | |||||
| 20 s | Infectivity, by CPE | 6.7 pfu/mL, >99.9% reduction | |||||
| 30 s | Infectivity, by CPE | <20 pfu/mL, >99.9% reduction | |||||
| Kitagawa | SARS-CoV-2 in liquid suspension | 222-nm Kr–Cl excimer lamp module | 0.1 mW/cm2 | 24 cm | 10 s | Viral titre by TCID50 | 2.34 ± 0.86 × 103, TCID50/mL, 0.94 log reduction |
| 30 s | Viral titre by TCID50 | 6.32 ± 0.0 × 101, TCID50/mL, 2.51 log reduction (undetectable levels) | |||||
| 10 s | RNA copy number by RTq-PCR | 5.75 ± 0.82 × 107 copies/test | |||||
| 30 s | RNA copy number by RTq-PCR | 3.41 ± 1.08 × 107 copies/test | |||||
| 60 s | RNA copy number by RTq-PCR | 2.95 ± 0.41 × 107 copies/test | |||||
| 300 s | RNA copy number by RTq-PCR | 3.03 ± 1.73 × 107 copies/test | |||||
| Ratnesar-Shumate | SARS-Cov-2 (USA-WA1/2020) in simulated saliva | Solar simulator with a xenon arc lamp | 1.6 W/m2 UVB | Not reported | 6.8 min | Inactivation rate, by TCID50 | 90% inactivation |
| 0.7 W/m2 UVB | Not reported | 8 min | Inactivation rate, by TCID50 | 90% inactivation | |||
| 0.3 W/m2 UVB | Not reported | 12.8 min | Inactivation rate, by TCID50 | 90% inactivation | |||
| SARS-Cov-2 (USA-WA1/2020) in growth medium (gMEM) | Solar simulator with a xenon arc lamp | 1.6 W/m2 UVB | Not reported | 14.3 min | Inactivation rate, by TCID50 | 90% inactivation | |
| 0.7 W/m2 UVB | Not reported | 17.6 min | Inactivation rate, by TCID50 | 90% inactivation | |||
| Sabino | SARS-CoV-2 in liquid suspension | Mercury UVC lamp (254 nm) | 0.016 mJ/cm2 (2.2 mW/cm2) | 30 cm | 0.01 s | Inactivation, by lethal dose | LD90 (viral inactivation 90%) |
| 108.714 mJ/cm2 (2.2 mW/cm2) | 30 cm | 49.42 s | Inactivation, by lethal dose | LD99 (viral inactivation 99.999%) | |||
| Simmons | SARS-CoV-2 prepared in liquid suspension and dried on the test surface | PX-UV robot model PXUV4D | Not reported | 1 m | 1 min | Decrease of infectivity titre, by plaque assay | 2.67 pfu/mL (log10), 99.97% reduction |
| 2 min | Decrease of infectivity titre, by plaque assay | <1.66 pfu/mL (log10), >99.997% reduction | |||||
| 5 min | Decrease of infectivity titre, by plaque assay | <2.08 pfu/mL (log10), >99.992% reduction |
CPE, cytopathic effect; LD, lethal dose; pfu, plaque-forming unit; RTqPCR, real-time quantitative polymerase chain reaction; TCID50, 50% tissue culture infectious dose; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Results of ultraviolet (UV) light interventions on SARS-CoV-1, MERS-CoV and human coronaviruses in included studies
| Reference | Virus | UV source | Intensity (irradiance) | Distance | Exposure time | Outcome | Results |
|---|---|---|---|---|---|---|---|
| Ansaldi | SARS-CoV-1 in liquid suspension | Not reported | 40 mW/cm2 | Not reported | <2 min | Infectivity, by inoculation in cell culture | Complete inhibition of viral replication |
| 40 mW/cm2 | Not reported | <2 min | Genome integrity by nested RT-PCR | Damaged | |||
| Darnell | SARS-CoV-1 (Urbani strain) in liquid suspension | UVC (254 nm) | 4,016 μW/cm2 | 3 cm | 15 min | Inactivation by TCID50 assay and by CPE | Complete |
| UVA (365 nm) | 2,133 μW/cm2 | 3 cm | 15 min | Inactivation by TCID50 assay and by CPE | No effect | ||
| Duan | SARS-CoV-1 (CoV-P9 strain) in liquid suspension | UVC (260 nm) | >90 μW/cm2 (UV dose >162 mW∗s/cm2 after 30 min) | 80 cm | 60 min | Infectivity, by CPE | Cells with no signs of CPE |
| Kariwa | SARS-CoV-1 (Hanoi strain) in liquid suspension | Not reported | 134 μW/cm2 | Not reported | 60 min | Viral titre reduction, by TCID50 | Still detectable |
| Bedell | MERS-CoV droplets | Triple UVC emitter | Not reported | 122 cm | 5 min | Viral titre reduction by plaque counts | Reduction of 5.91 log10 undetectable levels (mean of triplicate samples) |
| Bucknall | Coronavirus strain 229E in liquid suspension (2% fetal calf serum) | 1 emitter | Not reported | 45 cm | 7 min | Viral titre reduction by CPE, measured by TCID50 | <2 log10 TCID50/0.2 mL |
| Inactivation rate | 0.005 log/min | ||||||
| Coronavirus strain 229E in liquid suspension (0.2% bovine plasma albumin) | 1 emitter | Not reported | 45 cm | 30 s | Viral titre reduction by CPE, measured by TCID50 | 2 log10 TCID50/0.2 mL | |
| Inactivation rate | 0.08 log/min | ||||||
| Coronavirus strain OC43 in liquid suspension (2% fetal calf serum) | 1 emitter | Not reported | 45 cm | 11 min | Viral titre reduction by hemadsorption | around 1 log10 TCID50/0.2 mL | |
| Inactivation rate | 0.005 log/min | ||||||
| Coronavirus strain OC43 in liquid suspension (0.2% bovine plasma albumin) | 1 emitter | Not reported | 45 cm | 40 s | Viral titre reduction by hemadsorption | 2 log10 TCID50/0.2 mL | |
| Inactivation rate | 0.11 log/min | ||||||
| Buonanno | HCoV-229E (VR-740) aerosolized | 12-W 222-nm KrCl excimer lamp module | 100 μW/cm2 (1,7 mJ/cm2) | 22 cm | 20 s | Viral titre reduction, by TCID50 and CPE | 99.9% inactivation rate (constant k = 4.1 cm2/mJ) |
| HCoV-OC43 (VR-1558) aerosolized | 12-W 222-nm KrCl excimer lamp module | 100 μW/cm2 (1.2 mJ/cm2) | 22 cm | 20 s | Viral titre reduction, by TCID50 and CPE | 99.9% inactivation rate (constant k = 5.9 cm2/mJ) | |
| Gerchman | HCoV-OC43 | 267-nm rectangular LED system | 5.7 mJ/cm2 | Not reported | Not reported | Viral titre reduction by ICC-RTqPCR | 3 log10 pfu/mL (defined as limit of quantification) |
| 279-nm circular LED system | 7.0 mJ/cm2 | Not reported | Not reported | Viral titre reduction by ICC-RTqPCR | 3 log10 pfu/mL (defined as limit of quantification) | ||
| 286-nm rectangular LED system | 12.9 mJ/cm2 | Not reported | Not reported | Viral titre reduction by ICC-RTqPCR | 3 log10 pfu/mL (defined as limit of quantification) | ||
| 297-nm circular LED system | 32.0 mJ/cm2 | Not reported | Not reported | Viral titre reduction by ICC-RTqPCR | 3 log10 pfu/mL (defined as limit of quantification) |
CPE, cytopathic effect; HCoV, human coronavirus; ICC-RTqPCR, integrated cell culture real-time quantitative polymerase chain reaction; LED, light-emitting diode; MERS-CoV, Middle East respiratory syndrome–related coronavirus; pfu, plaque-forming unit; RT-PCR, real-time polymerase chain reaction; TCID50, 50% tissue culture infectious dose; SARS-CoV-1, severe acute respiratory syndrome coronavirus 1.
Results of ultraviolet (UV) light interventions on animal coronaviruses in included studies
| Reference | Virus | UV source | Intensity (irradiance) | Distance | Exposure time | Outcome | Results |
|---|---|---|---|---|---|---|---|
| Bedell | Dried MHV-A59 | Not reported | Not reported | 122 cm | 10 min | Viral titre reduction by plaque counts | Reduction of 6.11 log10 undetectable (mean of triplicate samples) |
| Saknimit | MHV-2 in liquid suspension | 1 emitter 15 W | Not reported | 1 m | 15 min | Decrease of infectivity titre, by plaque assay | >4.67 log pfu/0.1 mL (complete) |
| MHV-N in liquid suspension | 1 emitter 15 W | Not reported | 1 m | 15 min | Decrease of infectivity titre, by plaque assay | >3.34 log pfu/0.1 mL (complete) | |
| Walker | Aerosolized MHV | 6 emitters 36 W (254 nm UVC) | Radiant exposure (UV dose) = 599 μW∗S/cm2 (after 16.2 s) | Not reported | 16.2 s | Percent survival (100 × (number of plaques in the presence of UV exposure)/(number of plaques in the absence of UV exposure)) | 12% survival |
| Pratelli | CCV (S378 Strain) in liquid suspension | UVC | 27.1 μW/cm2 at 1-m distance | 4 cm | 72 h | Viral titre reduction, by TCID50 | 2 TCID50 (log10)/50 μL |
| Saknimit | CCV in liquid suspension | Not reported | Not reported | 1 m | 15 min | Decrease of infectivity titre, by plaque assay | >3.84 log pfu/0.1 mL (complete) |
| Morilla | TGE (Illinois strain) in liquid suspension | 1 emitter 8 W | Not reported | Not reported | 90 s | Inactivation, by log10 virus titre | Complete Log10 virus titre = 0 |
| TGE (M-HP strain) in liquid suspension | 1 emitter 8 W | Not reported | Not reported | 120 s | Inactivation, by log10 virus titre | Complete Log10 virus titre = 0 |
CCV, canine coronavirus; MHV, murine hepatitis virus; pfu, plaque-forming unit; TCID50, 50% tissue culture infectious dose; TGE, transmissible gastroenteritis of swine coronavirus.